PTGS2 and ovarian cancer: Gartung et al. (24) demonstrated that dual inhibition of cyclooxygenase 2 (COX-2) and soluble epoxide hydrolase (sEH) suppresses the release of these proinflammatory factors, slows ovarian cancer progression, and prolongs patient survival.